Richard Schwartz
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Sandell and colleagues discuss the benefits and risks of experiential training in psychedelic therapy for therapists, including potential therapeutic and theoretical functions, as well as risks like dual relationships and
Emma Hapke, Daniel Rosenbaum
Panel of experts explores psychedelics' role in conflict resolution, restorative justice, and peace-building. Discussion includes research, experiences, and ethical considerations for integrating psychedelics into transformative processes.
Therapists and religious professionals discuss ethical considerations in using psychedelics with vulnerable individuals, emphasizing the need for integrity and accountability in the psychedelic profession.
Cedar Barstow, Jennifer C Jones
Psychedelic-assisted therapy commonly involves experiences of self-love, love towards others, love received, and being in love. Research explores these experiences' healing potential and integration in therapy.
Lauren Taus, a psychedelic assisted therapist, discusses a new approach to drugs, family, and healing in therapy sessions and educational programs at Inbodied Life.
Psychedelic research faces challenges balancing methodological rigor with preserving subjective experiences in clinical trials, aiming to avoid bias while capturing the full impact of psychedelics on participants.
Ingmar Gorman, Erika Dyck, Tehseen Noorani
Stanislav Grof, a pioneer in psychedelic research, presents the Grof® Legacy Training on 'holotropic' states of consciousness, with colleagues from international psychedelic training programs.
Brigitte Grof, Stanislav Grof, Diane Haug, Javier Charme, Neil Hannon, Jay Dufrechou
Artificial Intelligence and psychedelics share complexities as powerful tools impacting humanity's reality and choices. Understanding their potential and regulating them ethically are urgent imperatives for positive impact.
Alexander Beiner, De Kai
MDMA's therapeutic mechanism differs from classical psychedelics, showing potential for treating CNS disorders. Shulgin's 1970s research inspired exploration of modifying MDMA's structure and developing novel compounds for improved effects.
Matthew Baggott